Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
- 31 July 2004
- journal article
- clinical trial
- Published by Elsevier BV in Lung Cancer
- Vol. 45 (1), 93-104
- https://doi.org/10.1016/j.lungcan.2004.01.010
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJama-Journal Of The American Medical Association, 2003
- Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?Journal of Clinical Oncology, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumorsAnnals of Oncology, 2003
- Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2003
- Severe acute interstitial pneumonia and gefitinibThe Lancet, 2003
- Women and lung cancer: does oestrogen play a role?The Lancet Oncology, 2001
- Uterine and Vaginal Organ Growth Requires Epidermal Growth Factor Receptor Signaling from Stroma*Endocrinology, 1998
- Uterine and Vaginal Organ Growth Requires Epidermal Growth Factor Receptor Signaling from StromaEndocrinology, 1998
- Cigarette smoking and p53 mutations in lung cancer and bladder cancer.Environmental Health Perspectives, 1996